Alembic Pharma Gets USFDA Nod for Generic Hypertension Treatment
By Rediff Money Desk, New Delhi Oct 21, 2024 13:33
Alembic Pharmaceuticals receives USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules used to treat hypertension, offering a cost-effective alternative to the brand-name drug Dilacor XR.
New Delhi, Oct 21 (PTI) Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic version of Diltiazem Hydrochloride extended-release capsules used to treat hypertension.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg, the company said in a statement.
These are therapeutically equivalent to the reference listed drug product (RLD), Dilacor XR Extended-Release Capsules, 120 mg, 180 mg, and 240 mg of Allergan Sales LLC, it added.
Diltiazem Hydrochloride extended-release capsules are indicated for treatment of hypertension. The drug may be used alone or in combination with other antihypertensive medications, such as diuretics. It is also indicated for the management of chronic stable angina, the company said.
Citing IQVIA data, Alembic Pharma said Diltiazem Hydrochloride extended-release capsules 120 mg, 180 mg, and 240 mg have an estimated market size of USD 28.2 million for 12 months ended June 2024.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg, the company said in a statement.
These are therapeutically equivalent to the reference listed drug product (RLD), Dilacor XR Extended-Release Capsules, 120 mg, 180 mg, and 240 mg of Allergan Sales LLC, it added.
Diltiazem Hydrochloride extended-release capsules are indicated for treatment of hypertension. The drug may be used alone or in combination with other antihypertensive medications, such as diuretics. It is also indicated for the management of chronic stable angina, the company said.
Citing IQVIA data, Alembic Pharma said Diltiazem Hydrochloride extended-release capsules 120 mg, 180 mg, and 240 mg have an estimated market size of USD 28.2 million for 12 months ended June 2024.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.53 ( -5.43)
- 55303244
- Srestha Finvest
- 0.74 ( -3.90)
- 39269402
- Standard Capital
- 1.16 (+ 0.87)
- 24022914
- Filatex Fashions
- 1.13 (+ 4.63)
- 21148211
- Rajnish Wellness
- 3.08 (+ 1.65)
- 18301420
MORE NEWS
Niva Bupa, Paras Healthcare Get Sebi Nod for IPOs
Niva Bupa Health Insurance and Paras Healthcare have received Sebi's approval to raise...
GreenLine Adds 1,000 LNG Trucks for...
GreenLine Mobility Solutions Ltd, a leader in green logistics, will add 1,000 LNG...
Afcons Infrastructure IPO Price Fixed at Rs...
Afcons Infrastructure, a Shapoorji Pallonji group company, has fixed the price band for...